Navigation Links
Journal of Cardiothoracic Surgery Publishes 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient
Date:8/21/2013

Tucson, AZ (PRWEB) August 21, 2013

SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that doctors at EJK Duisburg in Germany have published the first case report detailing use of single-site cannulation with extracorporeal membrane oxygenation (ECMO) to successfully treat adult respiratory distress syndrome in a patient implanted with the SynCardia temporary Total Artificial Heart. The case report was published in the August issue of the Journal of Cardiothoracic Surgery.

Before the Total Artificial Heart implant, the 55-year-old patient was supported by veno-arterial ECMO due to refractory cardiogenic shock and severe respiratory failure. Once the Total Artificial Heart was implanted, the patient was weaned from extracorporeal circulation. However, due to pre-existing respiratory failure, doctors decided to implement veno-venous ECMO using a single-site bicaval dual-lumen catheter placed in the right internal jugular vein instead of conventional dual-site cannulation.

“In this context single-site veno-venous cannulation proved to have numerous advantages: it is simple to perform, it minimizes the risk of cannula dislodgement during patient care, reduces the risk of catheter related infections and finally allows early sternum closure,” according to the report written by Dr. Sotirios Spiliopoulos, surgeons Dr. Guenes Dogan and Dr. Dilek Guersoy, intensivist Dr. Maria Rosario Serrano and Prof. Reiner Koerfer and Prof. Gero Tenderich, the implanting surgeon.

“Single-site venous cannulation could be a reasonable alternative to conventional cannulation for ECMO support in SynCardia Total Artificial Heart patients with an adult respiratory distress syndrome,” the report concluded.

“This is an excellent case report,” said Dr. Francisco Arabia, who has implanted more than 100 SynCardia Total Artificial Hearts. Arabia co-authored one of the articles cited in the August case report. That article dealt with parallel ECMO and artificial heart applications. He has proctored the first implant at more than a dozen hospitals qualifying these centers of excellence to become SynCardia Certified Centers.

###

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies."

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition: here.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11045771.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
2. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
3. BioStorage Technologies Mike Reffeitt Named "CFO of the Year" by Indianapolis Business Journal
4. 2011-2012 Michael E. DeBakey Journalism Award Winners Announced
5. Elsevier Launches New Journal: Learning, Culture and Social Interaction
6. Journal of Renewable and Sustainable Energy highlights energy trends in China
7. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
9. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
10. Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Massive, Ultra-Resolution Images
11. Elsevier Launches New Journal: Performance Enhancement & Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive results of ... devastating genetic disease that leads to a sudden and rapid loss of central vision. ... 11778, 14484 and 3460 mutations and having experienced the onset of symptoms more than ...
(Date:4/27/2017)... Yorba Linda, Ca (PRWEB) , ... April 27, ... ... will hear from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin ... signs that prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Volunteers supported by ... engineers, and industry professionals in visiting U.S. Congressional offices in Washington, D.C., yesterday ... world photonics industry. , This year, National Photonics Initiative (NPI) Congressional ...
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and ... 2022", published by MarketsandMarkets, the market is expected to be worth USD 18.98 ... Continue Reading ... ...      ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
Breaking Biology News(10 mins):